Results 101 to 110 of about 260,718 (281)

LDAcoop: Integrating non‐linear population dynamics into the analysis of clonogenic growth in vitro

open access: yesMolecular Oncology, EarlyView.
Limiting dilution assays (LDAs) quantify clonogenic growth by seeding serial dilutions of cells and scoring wells for colony formation. The fraction of negative wells is plotted against cells seeded and analyzed using the non‐linear modeling of LDAcoop.
Nikko Brix   +13 more
wiley   +1 more source

Plecstatin inhibits hepatocellular carcinoma tumorigenesis and invasion through cytolinker plectin

open access: yesMolecular Oncology, EarlyView.
The ruthenium‐based metallodrug plecstatin exerts its anticancer effect in hepatocellular carcinoma (HCC) primarily through selective targeting of plectin. By disrupting plectin‐mediated cytoskeletal organization, plecstatin inhibits anchorage‐dependent growth, cell polarization, and tumor cell dissemination.
Zuzana Outla   +10 more
wiley   +1 more source

Prioritisation of data-poor pharmaceuticals for empirical testing and environmental risk assessment

open access: yesEnvironment International
There are more than 3,500 active pharmaceutical ingredients (APIs) on the global market for human and veterinary use. Residues of these APIs eventually reach the aquatic environment.
Cristiana Cannata   +7 more
doaj   +1 more source

Therapeutic strategies for MMAE‐resistant bladder cancer through DPP4 inhibition

open access: yesMolecular Oncology, EarlyView.
We established monomethyl auristatin E (MMAE)‐resistant bladder cancer (BC) cell lines by exposure to progressively increasing concentrations of MMAE in vitro. RNA sequencing showed DPP4 expression was increased in MMAE‐resistant BC cells. Both si‐DPP4 and the DPP4 inhibitor sitagliptin suppressed the viability of MMAE‐resistant BC cells.
Gang Li   +10 more
wiley   +1 more source

Evolutionary trends in Bombella apis CRISPR-Cas systems

open access: yesmSystems
Bacteria and archaea employ a rudimentary immune system, CRISPR-Cas, to protect against foreign genetic elements such as bacteriophage. CRISPR-Cas systems are found in Bombella apis. B.
Carrie L. Ganote   +4 more
doaj   +1 more source

Programming patterns and development guidelines for Semantic Sensor Grids (SemSorGrid4Env)

open access: yes, 2011
The web of Linked Data holds great potential for the creation of semantic applications that can combine self-describing structured data from many sources including sensor networks.
De Roure, David   +4 more
core  

Infrared laser sampling of low volumes combined with shotgun lipidomics reveals lipid markers in palatine tonsil carcinoma

open access: yesMolecular Oncology, EarlyView.
Nanosecond infrared laser (NIRL) low‐volume sampling combined with shotgun lipidomics uncovers distinct lipidome alterations in oropharyngeal squamous cell carcinoma (OPSCC) of the palatine tonsil. Several lipid species consistently differentiate tumor from healthy tissue, highlighting their potential as diagnostic markers.
Leonard Kerkhoff   +11 more
wiley   +1 more source

The complete mitochondrial genome of wild honeybee Apis florea (Hymenoptera: Apidae) in south-western China

open access: yesMitochondrial DNA. Part B. Resources, 2017
We sequenced almost complete mitochondrial genome of Apis florea (Insecta: Hymenoptera: Apocrita: Apidae) with length of 15,933 bp. The genome has similar codon usage and gene organization to those of mitogenome reported for other Hymenoptera.
Jie Yang, Jianxin Xu, Shaoyu He, Jie Wu
doaj   +1 more source

APIs and Restful APIs [PDF]

open access: yesInternational Journal of Trend in Scientific Research and Development, 2018
Mithilesh Tarkar, Ameya Parker
openaire   +1 more source

Recurrent cancer‐associated ERBB4 mutations are transforming and confer resistance to targeted therapies

open access: yesMolecular Oncology, EarlyView.
We show that the majority of the 18 analyzed recurrent cancer‐associated ERBB4 mutations are transforming. The most potent mutations are activating, co‐operate with other ERBB receptors, and are sensitive to pan‐ERBB inhibitors. Activating ERBB4 mutations also promote therapy resistance in EGFR‐mutant lung cancer.
Veera K. Ojala   +15 more
wiley   +1 more source

Home - About - Disclaimer - Privacy